Research programme: histone deacetylase-6 protein inhibitors - Karus Therapeutics

Drug Profile

Research programme: histone deacetylase-6 protein inhibitors - Karus Therapeutics

Alternative Names: HDAC-6 inhibitors - Karus; HDAC6i - Karus; KAR 2581; KAR 3000; KAR 3166

Latest Information Update: 28 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; Kings College London; Queen Elizabeth Hospital
  • Class Antineoplastics; Depsipeptides; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours
  • Research Inflammation; Psoriasis; Rheumatoid arthritis
  • No development reported Transplant rejection

Most Recent Events

  • 28 Aug 2013 Early research in Cancer in United Kingdom (PO)
  • 28 Aug 2013 Early research in Inflammation in United Kingdom (PO)
  • 28 Aug 2013 Early research in Psoriasis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top